首页> 美国卫生研究院文献>Journal of Translational Medicine >Interferon-γ Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses
【2h】

Interferon-γ Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune Responses

机译:卡介苗诱导树突状细胞成熟过程中添加的干扰素-γ刺激强大的Th1免疫反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dendritic cells (DC) are increasingly prepared in vitro for use in immunotherapy trials. Mature DC express high levels of surface molecules needed for T cell activation and are superior at antigen-presentation than immature DC. Bacillus Calmette-Guerin (BCG) is one of several products known to induce DC maturation, and interferon (IFN)-γ has been shown to enhance the activity of DC stimulated with certain maturation factors. In this study, we investigated the use of IFN-γ in combination with the powerful maturation agent, BCG. The treatment of immature DC with IFN-γ plus BCG led to the upregulation of CD54, CD80, and CD86 in comparison with BCG treatment alone. In MLR or recall immune responses, the addition of IFN-γ at the time of BCG-treatment did not increase the number of antigen-specific T cells but enhanced the development of IFN-γ-producing Th1 cells. In primary immune responses, on the other hand, BCG and IFN-γ co-treated DC stimulated higher proportions of specific T cells as well as IFN-γ secretion by these T cells. Thus the use of IFN-γ during BCG-induced DC maturation differentially affects the nature of recall versus naïve antigen-specific T-cell responses. IFN-γ co-treatment with BCG was found to induce IL-12 and, in some instances, inhibit IL-10 secretion by DC. These findings greatly enhance the potential of BCG-matured dendritic cells for use in cancer immunotherapy.
机译:越来越多地在体外制备树突状细胞(DC),用于免疫疗法试验。成熟的DC表达高水平的T细胞活化所需的表面分子,并且在抗原呈递方面比未成熟的DC优越。卡介苗芽孢杆菌(BCG)是已知可诱导DC成熟的几种产品之一,干扰素(IFN)-γ已显示出可增强某些成熟因子刺激的DC活性。在这项研究中,我们调查了将IFN-γ与功能强大的成熟剂BCG结合使用的情况。与单独的BCG治疗相比,用IFN-γ加BCG治疗未成熟DC导致CD54,CD80和CD86上调。在MLR或回忆免疫反应中,在BCG处理时添加IFN-γ不会增加抗原特异性T细胞的数量,但会增强产生IFN-γ的Th1细胞的发育。另一方面,在初次免疫反应中,BCG和IFN-γ共同处理的DC刺激了更高比例的特异性T细胞以及这些T细胞的IFN-γ分泌。因此,在BCG诱导的DC成熟过程中使用IFN-γ会不同地影响召回与原始抗原特异性T细胞反应的性质。已发现与BCG的IFN-γ共同治疗可诱导IL-12,在某些情况下可抑制DC分泌IL-10。这些发现大大增强了卡介苗成熟的树突状细胞用于癌症免疫治疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号